BioCentury
ARTICLE | Clinical News

A first-in-class approval for rare anemia could be next step for Sanofi’s sutimlimab

November 23, 2019 1:18 AM UTC

Having met the primary endpoint in the pivotal CARDINAL trial, Sanofi’s sutimlimab could become the first approved therapy for primary cold agglutinin disease.

According to the company, the data are the first Phase III results for a complement inhibitor in the indication, which is a rare autoimmune hemolytic anemia in which complement induces antibody binding of red blood cells and triggers erythrocyte destruction...